Matches in Wikidata for { <http://www.wikidata.org/entity/Q93218006> ?p ?o ?g. }
Showing items 1 to 59 of
59
with 100 items per page.
- Q93218006 description "article scientifique publié en 2020" @default.
- Q93218006 description "artículu científicu espublizáu n'abril de 2020" @default.
- Q93218006 description "im April 2020 veröffentlichter wissenschaftlicher Artikel" @default.
- Q93218006 description "scientific article published on 24 April 2020" @default.
- Q93218006 description "wetenschappelijk artikel" @default.
- Q93218006 description "наукова стаття, опублікована 24 квітня 2020" @default.
- Q93218006 name "A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of th" @default.
- Q93218006 name "A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of th" @default.
- Q93218006 type Item @default.
- Q93218006 label "A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of th" @default.
- Q93218006 label "A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of th" @default.
- Q93218006 prefLabel "A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of th" @default.
- Q93218006 prefLabel "A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of th" @default.
- Q93218006 P1433 Q93218006-455634F4-6D78-45E5-BB2E-DC4E56BFD057 @default.
- Q93218006 P1476 Q93218006-455108F9-8734-4952-8CC5-7754EA108E34 @default.
- Q93218006 P2093 Q93218006-27D61E72-A672-4DD4-86AB-821D9E99E11D @default.
- Q93218006 P2093 Q93218006-3EC46E0E-F7F1-438E-9A95-024C6059DA8D @default.
- Q93218006 P2093 Q93218006-8810A7EA-CAE1-4F5F-AC44-2D62EEA27043 @default.
- Q93218006 P2093 Q93218006-910610D8-326E-4C55-9A86-38EFF9D53975 @default.
- Q93218006 P2093 Q93218006-979016C5-B394-491A-8092-88A2BFCCA049 @default.
- Q93218006 P2093 Q93218006-B05FC2D2-333A-4198-8928-32AC4BC9B968 @default.
- Q93218006 P2093 Q93218006-B42484EF-E3A8-4805-B474-A1ABE7BFD4D6 @default.
- Q93218006 P2093 Q93218006-B550D5D4-0707-4A6C-AA72-D1898A2AD20C @default.
- Q93218006 P2093 Q93218006-CB0AADEB-4D09-487A-BEA1-AD5FF65251D8 @default.
- Q93218006 P2093 Q93218006-D3B62569-8173-4324-A256-F9ED35375D29 @default.
- Q93218006 P2093 Q93218006-D99ADB53-6681-4745-A2F9-8C522CBF1DE5 @default.
- Q93218006 P2093 Q93218006-FFF50B2F-5DC9-4759-B5F3-0ED59EFC9EF8 @default.
- Q93218006 P31 Q93218006-732E855E-136A-4BA1-A173-5CD348E82C82 @default.
- Q93218006 P356 Q93218006-F6272E77-5CA2-4A2B-8D55-E906EC5F1A47 @default.
- Q93218006 P50 Q93218006-D54A2E2C-4329-4B4F-8866-4EB9DC50BC8D @default.
- Q93218006 P577 Q93218006-0A1C75C3-991C-409B-A896-C3BF14EE7F66 @default.
- Q93218006 P698 Q93218006-431BB394-E3F2-44F3-BDBF-310C4E76D9F5 @default.
- Q93218006 P921 Q93218006-5BF644D1-79BB-4354-AF74-EC113CD6E18E @default.
- Q93218006 P921 Q93218006-B62D7628-382E-4260-B70D-DCC8697344D5 @default.
- Q93218006 P932 Q93218006-619BF6AC-7DC9-4688-A6AD-E298F4FBB122 @default.
- Q93218006 P356 S00277-020-04005-6 @default.
- Q93218006 P698 32333154 @default.
- Q93218006 P1433 Q15766509 @default.
- Q93218006 P1476 "A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysis" @default.
- Q93218006 P2093 "Deok Hwan Yang" @default.
- Q93218006 P2093 "Dok Hyun Yoon" @default.
- Q93218006 P2093 "Gyeong-Won Lee" @default.
- Q93218006 P2093 "Min Kyoung Kim" @default.
- Q93218006 P2093 "Sang Eun Yoon" @default.
- Q93218006 P2093 "Seok Jin Kim" @default.
- Q93218006 P2093 "Won Seog Kim" @default.
- Q93218006 P2093 "Yeung-Chul Mun" @default.
- Q93218006 P2093 "Yoon Seok Choi" @default.
- Q93218006 P2093 "Young Hyeh Ko" @default.
- Q93218006 P2093 "Young Rok Do" @default.
- Q93218006 P2093 "Youngil Koh" @default.
- Q93218006 P31 Q13442814 @default.
- Q93218006 P356 "10.1007/S00277-020-04005-6" @default.
- Q93218006 P50 Q92139867 @default.
- Q93218006 P577 "2020-04-24T00:00:00Z" @default.
- Q93218006 P698 "32333154" @default.
- Q93218006 P921 Q5984881 @default.
- Q93218006 P921 Q6900 @default.
- Q93218006 P932 "7237534" @default.